Randomized controlled trial comparing superovulation with letrozole versus recombinant follicle-stimulating hormone combined with intrauterine insemination for couples with unexplained infertility who had failed clomiphene citrate stimulation and intrauterine insemination
Randomized controlled trial comparing superovulation with letrozole versus recombinant follicle-stimulating hormone combined with intrauterine insemination for couples with unexplained infertility who had failed clomiphene citrate stimulation and intrauterine insemination
复制标题
DOI：
10.1016/j.fertnstert.2007.06.099
复制
发表时间：
2008-09-01
影响因子：
6.7
通讯作者：
Creatsas, George K.
中科院分区：
文献类型：
--
作者：
Gregoriou, Odysseas;Vlahos, Nikos F.;Creatsas, George K.
目的：比较来曲唑与重组 FSH 卵巢刺激联合 IUI 对一组克罗米芬 (CC) 和 IUI 后未能受孕的患者的疗效。设计：对人类受试者进行前瞻性随机试验。地点：大学生育中心。患者：50 对不明原因不孕夫妇，在 3 个周期的 CC 联合 IUI 后未能受孕。干预措施：夫妇被随机分组使用来曲唑或重组 FSH 联合 IUI 进行超数排卵。主要结果指标：每个治疗周期的临床妊娠和每对夫妇的临床妊娠。结果：来曲唑组每个周期的妊娠率 (PR) 为 8.9%，而促性腺激素 IUI 组为 14%。这导致每对夫妇的累积 PR 分别为 24% 和 36%，带回家婴儿率分别为 20% 和 28%。来曲唑组的子宫内膜厚度显着较低（7.1 +/- 2.3 vs 8.6 +/- 1.8）。结论：与促性腺激素相比，来曲唑卵巢刺激与可接受的 PR 相关，且成本、风险和患者不便显着降低。
Objective: To compare the efficacy of letrozole to recombinant FSH for ovarian stimulation combined with IUI in a group of patients that had failed to conceive after clomiphene citrate (CC) and IUI.Design: Prospective randomized trial with human subjects.Setting: University-based fertility center.Patient(s): Fifty couples with unexplained infertility that failed to conceive after three cycles of CC combined to IUI.Intervention(s): Couples were randomized to undergo superovulation either with letrozole or with recombinant FSH combined to IUI.Main Outcome Measure(s): Clinical pregnancy per cycle of treatment and clinical pregnancy per couple.Result(s): Pregnancy rate (PR) per cycle was 8.9% in the letrozole group as compared with 14% in the gonadotropin IUI group. This resulted in a cumulative PR per couple of 24% versus 36% and a take home baby rate of 20% versus 28%. Endometrial thickness was significantly lower in the letrozole group (7.1 +/- 2.3 vs 8.6 +/- 1.8).Conclusion(s): Ovarian stimulation with letrozole is associated with acceptable PRs compared with gonadotropin with significant less cost, risks, and patient inconvenience.